Back to all newsCAMBRIDGE, MA –March 25, 2021 – Caraway Therapeutics today announced that the Company is scheduled to participate at two upcoming virtual investor events in April 2021.
Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel CNS Day on April 1, 2021 at 2:30pm ET and the Company is participating in the Needham Annual Healthcare Conference on April 13, 2021.
“I look forward to discussing the details of Caraway’s approach to developing treatments for genetically-defined neurodegenerative and rare diseases at Needham’s and Stifel’s upcoming events,” said Williams. “Our approach to creating oral small molecule therapeutics is informed by genetic data and our unique insights into lysosomal function, and I am pleased to have the opportunity to share our recent scientific progress.”
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically-defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
Media Contact:
MacDougall
Caroline Rufo, PhD or Kari Watson
(781) 235-3060
crufo@macbiocom.com or kwatson@macbiocom.com